Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy. We now report final survival outcomes. METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. Analysis of survival was performed by means of two-sided stratified log-rank tests and Cox regression. Efficacy and safety were compared between the two groups, both overall and in subgroups. RESULTS: Of 707 patients who had undergone randomization, 694 had data available for analysis. The combination-therapy group had 247 deaths among 349 women (71%) and a median overall survival of 49.8 months, as compared with 261 deaths among 345 women (76%) and a median overall survival of 42.0 months in the anastrozole-alone group, a significant difference (hazard ratio for death, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03 by the log-rank test). In a subgroup analysis of the two strata, overall survival among women who had not received tamoxifen previously was longer with the combination therapy than with anastrozole alone (median, 52.2 months and 40.3 months, respectively; hazard ratio, 0.73; 95% CI, 0.58 to 0.92); among women who had received tamoxifen previously, overall survival was similar in the two groups (median, 48.2 months and 43.5 months, respectively; hazard ratio, 0.97; 95% CI, 0.74 to 1.27) (P = 0.09 for interaction). The incidence of long-term toxic effects of grade 3 to 5 was similar in the two groups. Approximately 45% of the patients in the anastrozole-alone group crossed over to receive fulvestrant. CONCLUSIONS: The addition of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. The results suggest that the benefit was particularly notable in patients without previous exposure to adjuvant endocrine therapy. (Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as well as impressive median survival to date (63.9 months) among women with HR-positive, HER2-negative advanced breast cancer. 16,20,22-29”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [28]
Citations
Cites
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 582
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Livingston, R. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201622 · Cited by 371
Self-citation
Cited by
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114663 · Cited by 791
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Analysis of Breast Cancer Mortality in the US—1975 to 2019
Caswell-Jin, J. L., Sun, L. P., Munoz, D., Lu, Y., Li, Y., Huang, H., Hampton, J. M., Song, J., Jayasekera, J., Schechter, C., et al. (2024) · JAMA · doi:10.1001/jama.2023.25881 · Cited by 284
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 214
Huppert, L. A., Gumusay, O., Idossa, D., & Rugo, H. S. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 164
“03).(126) Of note, the SWOG S0226 study enrolled more endocrine‐naive patients and used a higher dose of fulvestrant, which may explain the differences in outcomes.”
Drug repurposing for breast cancer therapy: Old weapon for new battle
Aggarwal, S., Verma, S. S., Aggarwal, S., & Gupta, S. C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.012 · Cited by 163
“Fulvestrant was first used in 2002 as a ‘SERD hormone therapy’ against HR HER2 advanced and metastatic breast cancer in post-menopausal women that were resistant to other hormone therapy [121].”
Endocrine-Resistant Breast Cancer: Mechanisms and Treatment
Hartkopf, A. D., Grischke, E., & Brucker, S. Y. (2020) · Breast Care · doi:10.1159/000508675 · Cited by 149
Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
McAndrew, N. P., & Finn, R. S. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00384 · Cited by 121
Rossi, V., Berchialla, P., Giannarelli, D., Nisticò, C., Ferretti, G., Gasparro, S., Russillo, M., Catania, G., Vigna, L., Mancusi, R. L., et al. (2019) · Cancers · doi:10.3390/cancers11111661 · Cited by 70
“SWOG Mehta Anastrozole Musculoskeletal pain, fatigue, hot flashes, mood alterations, GI symptoms 15% (each 1–4”
BackgroundDai, Y., Yu, X. M., Wei, J., Zeng, F., Li, Y., Yang, X., Luo, Q., & Zhang, Z. (2020) · Light Science & Applications · doi:10.1038/s41377-020-00399-0 · Cited by 69
Nagaraj, G., & Ma, C. X. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01552-2 · Cited by 53
Wang, Z., Cheng, Y., Chen, S., Shao, H., Chen, X., Wang, Z., Wang, Y., Zhou, H., Chen, T., Lin, N., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.37 · Cited by 46
“For metastatic BC, chemotherapy is recommended as it can prolong survival, decrease cancer-related complications, and improve quality of life (41).”
BackgroundTolaney, S. M., Im, Y.-H., Calvo, E., Lu, Y.-S., Hamilton, E., Forero-Torres, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0645 · Cited by 39
“The combination of fulvestrant plus anastrozole significantly prolonged overall survival (OS) compared with anastrozole alone in the first-line setting (3).”
BackgroundCarter, G. C., Sheffield, K. M., Gossai, A., Huang, Y., Zhu, Y. E., Bowman, L., Smyth, E. N., Mathur, R., Cohen, A. B., Rasmussen, E., et al. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1923468 · Cited by 40
Thomssen, C., Lüftner, D., Untch, M., Haidinger, R., Würstlein, R., Harbeck, N., Augustin, D., Briest, S., Ettl, J., Fasching, P. A., et al. (2020) · Breast Care · doi:10.1159/000505957 · Cited by 38
Ahmadieh-Yazdi, A., Mahdavinezhad, A., Tapak, L., Nouri, F., Taherkhani, A., & Afshar, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-46633-8 · Cited by 42
“Other drugs in the drug-DEGs network in this study have also found to be effective in the treatment of different metastatic cancers, such as breast cancer 72 and thyroid carcinoma 73 .”
BackgroundRosenberg, T., Montgomery, P. R., Hay, V., & Lattimer, R. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-032712 · Cited by 47
Updates in endocrine therapy for metastatic breast cancer
Manohar, P. M., & Davidson, N. E. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0255 · Cited by 40
Management of ER positive metastatic breast cancer
McAndrew, N. P., & Finn, R. S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.005 · Cited by 36
HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
Jerzak, K. J., Bouganim, N., Brezden‐Masley, C., Edwards, S. J., Gelmon, K. A., Henning, J., Hilton, J. F., & Sehdev, S. R. (2023) · Current Oncology · doi:10.3390/curroncol30060411 · Cited by 36
“Combination treatment with fulvestrant and anastrozole achieved improved OS compared with anastrozole alone in a SWOG Cancer Research Network trial [4].”
Ma, C. X., Suman, V. J., Sanati, S., Vij, K. R., Anurag, M., Leitch, A. M., Unzeitig, G. W., Hoog, J., Fernández-Martínez, A., Fan, C., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6038 · Cited by 32
An evaluation of fulvestrant for the treatment of metastatic breast cancer
Soleja, M., Raj, G. V., & Unni, N. G. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1651293 · Cited by 29
“more dramatic benefit of combination fulvestrant and anastrozole in patients who had no prior hormonal therapy [46].”
BackgroundSubtyping for pancreatic cancer precision therapy
Huang, X., Zhang, G., & Liang, T. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.005 · Cited by 33
Sammons, S. L., Shastry, M., Dent, S. F., Anders, C. K., & Hamilton, E. P. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.017 · Cited by 31
Mahadik, N. S., Bhattacharya, D., Padmanabhan, A., Sakhare, K. R., Narayan, K. P., & Banerjee, R. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1755 · Cited by 30
Spinello, A., Ritacco, I., & Magistrato, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646245 · Cited by 25
Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
Lerebours, F., Cabel, L., & Pierga, J. (2021) · Cancers · doi:10.3390/cancers13040902 · Cited by 30
“Fulvestrant is a selective ER degrader (SERD) that demonstrated a higher efficacy than AI as first-line therapy in the metastatic setting [15,16].”
BackgroundShen, L., Jin, X., Wang, X., Tou, L., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000745 · Cited by 27
“030).([24,25]) Of note, a larger percentage of participants in the SWOG trial were ET-naïve than in the FACT trial (59.”
ResultPaoletti, C., Barlow, W. E., Cobain, E. F., Bergqvist, M., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., Pusztai, L., Sharma, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1562 · Cited by 23
“Prior analyses (2, 3) had shown that the benefit of the combination was only seen in the subset without prior adjuvant tamoxifen treatment (N1⁄4 282/432; 65.”
BackgroundMethodSelf-citationShimoi, T., Sagara, Y., Hara, F., Toyama, T., & Iwata, H. (2020) · Breast Cancer · doi:10.1007/s12282-020-01054-7 · Cited by 23
“The updated results of SWOG 0266 showed improvement in overall survival by combination therapy with anastrozole and AI, especially among patients without receiving previous endocrine therapy [20].”
ResultAromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
Andrikopoulou, Α., Fiste, O., Liontos, M., Dimopoulos, M. A., & Zagouri, F. (2021) · Cancers · doi:10.3390/cancers13030465 · Cited by 21
“6%) in the anastrozole-treated population, while there were no fractures reported in the exemestane arm [49,50,55,61] (Table 1).”
BackgroundLiquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
Main, S. C., Cescon, D. W., & Bratman, S. V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.37 · Cited by 24
Gupta, K. K., Sharma, K. K., Chandra, H., Panwar, H., Bhardwaj, N., Altwaijry, N., Alsfouk, A. A., Dlamini, Z., Afzal, O., Altamimi, A. S. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950835 · Cited by 20
“Also, the administration of anastrozole is connected with less serious side effects than tamoxifen, such as fewer events of thromboembolism, ischemic cerebrovascular, and endometrial cancer but enhanced numbers of fractures following treatment (11).”
BackgroundInfluentialHormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options
Borella, F., Fucina, S., Mangherini, L., Cosma, S. D., Carosso, A. R., Cusato, J., Cassoni, P., Bertero, L., Katsaros, D., & Benedetto, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082157 · Cited by 24
Major clinical research advances in gynecologic cancer in 2019
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Lee, J., Lee, Y.-Y., Hansen, H. F., Mirza, M. R., & Kim, J. (2020) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2020.31.e48 · Cited by 19
“The final results regarding OS was reported this year [48].”
BackgroundThe Present and Future of Clinical Management in Metastatic Breast Cancer
Lin, P., & Laliotis, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195891 · Cited by 20
Shao, H., Zhao, M., Guan, A., Shao, T., Zhou, D., Yu, G., & Tang, W. (2024) · BMC Medicine · doi:10.1186/s12916-023-03238-2 · Cited by 21
Does adjuvant therapy reduce postmetastatic survival?
Fink, M. K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz159 · Cited by 18
Oceguera-Basurto, P. E., Topete, A., Oceguera‐Villanueva, A., Rivas‐Carrillo, J. D., Paz-Davalos, M., Ramos, A. Q., Toro‐Arreola, A. D., & Daneri‐Navarro, A. (2020) · Translational Cancer Research · doi:10.21037/tcr-19-1956 · Cited by 19
“In another study (72), 694 patients were analyzed and the overall survival among post-menopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the AI anastrozole along with the SERD, fulvestrant, as a first-line therapy was compared to that of patients who r…”
BackgroundResultMouabbi, J. A., Osborne, C. K., Schiff, R., & Rimawi, M. F. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06383-5 · Cited by 21
“03) durations than did anastrozole alone [27, 28].”
Toss, A., Venturelli, M., Sperduti, I., Molinaro, E., Isca, C., Barbieri, E., Piacentini, F., Omarini, C., Cortesi, L., Cascinu, S., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.011 · Cited by 17
Role of miRNAs in regulating responses to radiotherapy in human breast cancer
Chong, Z. X., Yeap, S. K., & Ho, W. Y. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1864048 · Cited by 16
Combined endocrine and targeted therapy in luminal breast cancer
Cesca, M. G., Pandolfi, N. C., Maciel, D., Lima, J., Sanches, S. M., & Ponde, N. F. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1960160 · Cited by 19
Huang, H., Wei, T., Zhang, A., Zhang, H., Kong, L., Li, Y., & Li, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-74746-1 · Cited by 25
“The addition of fulvestrant, an ER down-regulator, to anastrozole prolonged the overall survival by 7.8 months compared with anastrozole alone 18 .”
BackgroundInfluentialAwada, A. H., Gligorov, J., Jérusalem, G., Preusser, M., Singer, C. F., & Zielinski, C. C. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000565 · Cited by 14
Bergqvist, M., Nordmark, A., Williams, A., Paoletti, C., Barlow, W. E., Cobain, E. F., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., et al. (2023) · Biomarkers · doi:10.1080/1354750x.2023.2168063 · Cited by 13
“Details regarding eligibility and trial design are published elsewhere (Paoletti et al. 2021, Mehta et al. 2012, Mehta et al. 2019).”
BackgroundSelf-citationMohamed, A. S., Jourdain, I., Knorr, M., Elmi, A., Chtita, S., Scheel, R., Carsten Strohmann, B., & Hussien, M. A. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131979 · Cited by 13
Yang, C., Moi, S., Chuang, L., & Lin, Y. (2023) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2023.3342462 · Cited by 12
“In addition, CoxPH and LR have been used to assess the significance of features associated with survival outcome in cancer, which helps interpret the association between outcomes and risk features [17], [18], [19].”
Jing, M. X., Bi, X.-J., Yao, X., Cai, F.-Y., Liu, J., Fu, M., Kong, L., Liu, X., Zhang, L., He, S.-Y., et al. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1742145 · Cited by 12
The efficacy of gefitinib supplementation for breast cancer
Ye, J., Tian, T., & Chen, X. (2020) · Medicine · doi:10.1097/md.0000000000022613 · Cited by 13
Robertson, J. F. R., Shao, Z., Noguchi, S., Bondarenko, I., Panasci, L., Singh, S. R., Subramaniam, S., & Ellis, M. J. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.00994 · Cited by 17
“8,11,12 Ef fi cacy differences within treatment arms in patients with visceral versus nonvisceral disease emerged during the primary PFS analysis of FALCON and were consistent with other RCTs with fulvestrant.”
Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer
Valenza, C., & Curigliano, G. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115739 · Cited by 12
Moore, H. C. F., Barlow, W. E., Somlo, G., Gralow, J. R., Schott, A. F., Hayes, D. F., Kühn, P., Hicks, J. B., Welter, L. M., Dy, P. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3131 · Cited by 10
Self-citationEl-Emam, N. A., El‐Ashmawy, M. B., Mohamed, A. A. B., Habib, E. E., Thamotharan, S., Abdelbaky, M. S. M., García‐Granda, S., & Moustafa, M. A. (2024) · Pharmaceuticals · doi:10.3390/ph17091123 · Cited by 10
“Bemcen-tinib [11], letrozole [12], vorozole [13], and anastrazole [14] are currently used as an e ffi - cient treatment for di ff erent cancers.”
BackgroundMagno, E., & Bussard, K. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063407 · Cited by 12
“Fulvestrant may also be combined with an AI, which has been shown to improve overall survival over AI alone [144,145].”
BackgroundFulvestrant in hormone-positive advanced breast cancer: Real-world outcome
Dhanushkodi, M., Vaikundaraja, I. M., Radhakrishnan, V. S., Kalaiarasi, J., Mehra, N., Rajan, A., Selvarajan, G., Kesana, S., Ananthi, B., Iyer, P., et al. (2020) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_53_20 · Cited by 9
Patient-Derived Breast Cancer Bone Metastasis In Vitro Model Using Bone-Mimetic Nanoclay Scaffolds
Jasuja, H., Mohammadi, F. S., Kim, J., Gaba, A. G., Katti, D. R., & Katti, K. S. (2023) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1155/2023/5753666 · Cited by 9
“Median survival is about 3–5 years for hormonal receptor-positive metastatic breast cancer [8, 9] and 1–2 years for triple-negative metastatic breast cancer [10, 11].”
DREAM On, DREAM Off: A Review of the Estrogen Paradox in Luminal A Breast Cancers
Hugh, J. C., Haddon, L. S. J., & Githaka, J. M. (2024) · Biomedicines · doi:10.3390/biomedicines12061300 · Cited by 10
“Fulvestrant, particularly the 500 mg dose, may have superior activity in ER+PR+ tumors [78] and has been shown to prolong overall survival when added to Anastrazole in post-menopausal hormone-receptor-positive metastatic breast cancer patients [79].”
BackgroundLiao, W., Huang, J., Wu, Q., Wen, F., Zhang, N., Zhou, K., Bai, L., & Li, Q. (2019) · Breast Cancer · doi:10.1007/s12282-019-01034-6 · Cited by 8
Dawood, S. S., Konstantionva, M., Dent, R. A., Perazzo, F., Kim, S., Villarreal-Garza, C. M., Franco, S., Dai, M., & Simon, S. D. (2021) · BMC Proceedings · doi:10.1186/s12919-021-00224-5 · Cited by 10
“The OS benefit was more prominent in patients who had not received prior tamoxifen (Table 1) [26].”
BackgroundMethodHuang, X., Weng, X., Lin, S., Liu, Y., Luo, S., Wang, H., Ming, W., & Huang, P. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-036107 · Cited by 10
Julio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564067 · Cited by 10
Zhao, J., Zhao, H., Jia, T., Yang, S., & Wang, X. (2022) · Cancer Management and Research · doi:10.2147/cmar.s377784 · Cited by 8
“OS was defined as survival time from operation until death by any reason or last follow-up.(19) Patients were censored if no local recurrence and distant metastasis were detected at the last follow-up or on the date of death.”
BackgroundMethodMou, H., Wang, Z., Zhang, W., Li, G., Zhou, H., Yinwang, E., Wang, F., Sun, H., Xue, Y., Wang, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693689 · Cited by 10
MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer
Luan, R., He, M., Li, H., Bai, Y. Z., Wang, A., Sun, G., Zhou, B., Wang, M., Wang, C., Wang, S., et al. (2023) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00003-z · Cited by 10
“At present, endocrine therapy blocking ER α pathway is an exactly prevailing treatment for ER α -positive BCa (Mehta et al, 2019).”
Frassoldati, A., Biganzoli, L., Bordonaro, R., Cinieri, S., Conte, P., Laurentis, M. D., Mastro, L. D., Gori, S., Lauria, R., Marchetti, P., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0942 · Cited by 7
El-Emam, N. A., Moustafa, M. A., Mohamed, A. A. B., Blacque, O., Habib, E. E., Krishnan, V., Thamotharan, S., & El‐Ashmawy, M. B. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.141129 · Cited by 6
Wang, J., Han, Y., Wang, J., Li, Q., & Xu, B. (2022) · Cancers · doi:10.3390/cancers14246100 · Cited by 7
“However, in the subsequent publication with OS data, HR for patients stratified into endocrine-sensitive and -resistant were provided and the same were used for analysis [28].”
MethodLandmark trials in the medical oncology management of metastatic breast cancer
Lu, P., Santa-Maria, C. A., Ballinger, T. J., & Sheng, J. Y.-S. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.06.003 · Cited by 7
Chavez, J. A. S., Aristizabal, L. S. R., & Martínez, O. M. M. (2022) · Boletin Latinoamericano y del Caribe de plantas Medicinales y Aromaticas · doi:10.37360/blacpma.23.22.2.12 · Cited by 5
Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review
Yan, L., & Tao, P. (2025) · iLiver · doi:10.1016/j.iliver.2025.100186 · Cited by 6
“37 A network meta-analysis investigated the efficacy of CDK4/6 inhibitors combined with endocrine therapy using data from the MON-ALEESA 2, 37 PALOMA 2, 38 MONALEESA 7, 39 MONARCH 3, 40 FALCON, 36 SWOG, 41 and FACT.”
Fulvestrant enables better outcomes
Sidaway, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0211-7 · Cited by 4
Aghakouchakzadeh, M., Kakavand, H., Goldberg, A. J., Accordino, M. K., Trivedi, M. S., Raikhelkar, J., & Talasaz, A. H. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70149 · Cited by 3
“Based on the drug's landmark trial, the VTE risk with fulvestrant was not greater when compared with exemestane or placebo [21–23].”
Huang, X. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0246-5 · Cited by 3
“[1], reporting the combined treatment of anastrozole and fulvestrant increases long-term survival of patients with metastatic breast cancer, especially for those without receiving endocrine therapy [2, 3].”
BackgroundKrasniqi, E., Barchiesi, G., Mazzotta, M., Pizzuti, L., Villa, A., Barba, M., & Vici, P. (2020) · Medicine · doi:10.1097/md.0000000000021211 · Cited by 3
“Lessons: Eve plus Exe remains a valid option in HR+HER2– MBC. Abbreviations: Anas = anastrozole, Cape = capecitabine, ET = endocrine therapy, Eve = everolimus, Exe = exemestane, Fulv = fulvestrant, HER2– = human epidermal growth factor receptor 2 negative, HR+ = hormone receptor positive, MBC = metastatic breast cance…”
InfluentialOkwor, V. C., Okwor, C. J., Ukwuoma, M., Mitha, S. B., & Nweke, M. (2025) · Medical Principles and Practice · doi:10.1159/000545264 · Cited by 3
“Multiple studies have sought to investigate the effectiveness of different classes of hormonal therapy [47, 59, 60].”
Emerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Li, M. C., Xiong, Y., Liao, C., He, Y., Duan, S., Yi, F., Wei, Y., & Zhang, W. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05551-3 · Cited by 2
Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic
Abedin, Y., Madan, U., Graham, D. M. A., & Hellmann, M. C. (2022) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2022.100961 · Cited by 2
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00006-4 · Cited by 2
Rutherford, D. V., Medley, S., Henderson, N., Gersch, C. L., Vandenberg, T. A., Albain, K. S., Dakhil, S. R., Tirumali, N. R., Gralow, J. R., Hortobágyi, G. N., et al. (2023) · Pharmacogenomics · doi:10.2217/pgs-2023-0097 · Cited by 2
Self-citationAraya, C., Mino, B., Cerf, P. L., Gaete, F., Armisén, R., & Carvajal‐Hausdorf, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212246 · Cited by 2
Untch, M., Würstlein, R., Lüftner, D., Haidinger, R., Fasching, P. A., Augustin, D., Briest, S., Ettl, J., Forster, F. M. C., Kurbacher, C. M., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1139-9380 · Cited by 3
“According to a subgroup evaluation of the SWOG trial [31], the PFS/OS benefit is limited to patients who have not received prior adjuvant hormone therapy (tamoxifen), which is why an endocrine combination therapy may only represent an option for this specific subgroup of patients.”
Abdelrazeq, A. S., Ghabbour, H. A., Al-Wahaibi, L. H., Abdelbaky, M. S. M., García‐Granda, S., El-Emam, A. A.-R., Pathak, S. K., Srivastava, R., Maurya, A., Shukla, V. K., et al. (2023) · Polycyclic aromatic compounds · doi:10.1080/10406638.2023.2219362 · Cited by 2
“28,29 The triazole-based aromatase inhibitors Letrozole, 30 Vorozole 31 and anastrazole 32 are currently used as efficient therapies for the treatment of breast cancer.”
MethodDe, S. K. (2022) · Wiley eBooks · doi:10.1002/9783527838561.ch6 · Cited by 2
Parsonson, A. O., Sarkar, S., Brown, L., Low, G. K. K., Kiely, B. E., & Vasista, A. (2024) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14096 · Cited by 1
Okwor, V. C., Okwor, C. J., Ukwuoma, M., & Nweke, M. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241279019 · Cited by 1
Personalization of Endocrine Therapy in Hormone Receptor-Positive Breast Cancer
Fernandes, S., Batra, A., & Pushpam, D. (2024) · Springer eBooks · doi:10.1007/978-981-97-7755-6_24 · Cited by 1
Chemotherapeutic Protocols for the Treatment of Breast Cancer
Cavalcanti, I. D. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-10839-6_4 · Cited by 2
A review of therapeutic agents for breast cancer with potentially radiosensitizing properties
Zhang, Z., LIM, D. J., & Feng, Z. (2024) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2024.03.002 · Cited by 1
Majić, A., Bajić, Ž., Ban, M., Sedlar, I. T., Čerina, D., Miše, B. P., Strikić, A., Tomić, S., & Vrdoljak, E. (2025) · Cancers · doi:10.3390/cancers17132083 · Cited by 1
“…and clinically meaningfully improved outcomes in terms of progression-free survival (PFS) and overall survival (OS) in the metastatic setting in combination with AI, based on the results of SWOG S0226, and this questioned the role of such a combination in the early, neoadjuvant setting [12].”
Reduction in number to treat versus number needed to treat
Zhang, C., & Yin, G. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01246-5 · Cited by 1
“The S0226 trial [21] was a multi-center, randomized, open-label study with patients of metastatic breast cancer to evaluate the potential benefit of adding fulvestrant to anastrozole therapy versus anastrozole alone.”
BackgroundMethodA Review of Local and Systemic Therapy in Breast Cancer
Aydıner, A., Bayraktar, S., Yavuz, E., Şen, F., İbiş, K., Dinçer, M., Aslay, I., Cabıoğlu, N., Karanlık, H., & İğci, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-16792-9_44 · Cited by 1
Metastatic and Secondary Orbital Tumors
Lauer, S. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_70 · Cited by 1
Vorteil für Östrogenblocker-Kombi bei Brustkrebsmetastasen
Müller, T. M. (2019) · gynäkologie + geburtshilfe · doi:10.1007/s15013-019-1766-1
Vorteil für Östrogenblocker-Kombination
Müller, T. M. (2019) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-019-6650-6
Vorteil für Östrogenblocker-Kombination bei Brustkrebsmetastasen
Müller, T. H. (2019) · Im Focus Onkologie · doi:10.1007/s15015-019-0240-1
Kemik metastazlarında sistemik tedaviler
Şanlı, U. A., Karateke, M., & Almuradova, E. (2019) · Türk Ortopedi ve Travmatoloji Birliği Derneği · doi:10.14292/totbid.dergisi.2019.79
Metadata
- Authors
- Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Linden, H. M., Livingston, R. B., & Hortobagyi, G. N.
- Affiliations
- Seattle Cancer Care Alliance (US)
- From the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange (R.S.M.); the SWOG Statistics and Data Management Center (W.E.B., D.L.L.) and Seattle Cancer Care Alliance and University of Washington Medical Center (J.R.G., H.M.L.) — both in Seattle; Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); London Health Sciences Centre and the National Cancer Institute of Canada Clinical Trials Group, London, ON, Canada (T.A.V.); the Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-28
- Volume
- 380
- Issue
- 13
- Pages
- 1226-1234
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6885383
- OpenAlex
- W2925092419
- Cited by
- 126
- References
- 16
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 15 · 2023: 19 · 2022: 17 · 2021: 18 · 2020: 28 · 2019: 19
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UA Campus Repository (The University of Arizona) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute of the National Institutes of Health (CA180888, CA180819, CA180863, CA189808, CA180801,)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- fulvestrant, anastrozole, metastatic breast cancer, hormone receptor-positive breast cancer, aromatase inhibitors, overall survival, adjuvant tamoxifen, first-line therapy, postmenopausal women, treatment toxicity, progression-free survival, subgroup analysis, adjuvant endocrine therapy, adjuvant chemotherapy
- MeSH terms
- Fulvestrant, Anastrozole, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Metastasis, Postmenopause, Cross-Over Studies, Aromatase Inhibitors, Kaplan-Meier Estimate, Estrogen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.